Monogenic forms of hypercholesterolaemia have implicated key genes in the LDL-cholesterol transport pathway, including PCSK9, with PCSK9 monoclonal antibodies evolocumab and alirocumab now indicated for treatment of common hyperlipidaemia. The gene discussed is PCSK9; the disease is hyperlipidemia.